Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what discussions his Department has had with clinical bodies on the approach in the NHS to prescribing Ritalin for children with ADHD.

It is not appropriate for the Department of Health to be involved in operational decisions relating to the prescribing of methylphenidate (for which Ritalin is a trade name) in the treatment of Attention Deficit Hyperactivity Disorder. That is a matter for the National Institute for Health and Care Excellence, which is currently revising guidance on the use of methylphenidate and will be consulting widely on that new guidance which is expected in 2018.

It is not appropriate for the Department of Health to be involved in operational decisions relating to the prescribing of methylphenidate (for which Ritalin is a trade name) in the treatment of Attention Deficit Hyperactivity Disorder. That is a matter for the National Institute for Health and Care Excellence, which is currently revising guidance on the use of methylphenidate and will be consulting widely on that new guidance which is expected in 2018.